Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16662
Full metadata record
DC FieldValueLanguage
dc.contributor.authorField, Kathryn M-
dc.contributor.authorKing, Madeleine T-
dc.contributor.authorSimes, John-
dc.contributor.authorEspinoza, David-
dc.contributor.authorBarnes, Elizabeth H-
dc.contributor.authorSawkins, Kate-
dc.contributor.authorRosenthal, Mark A-
dc.contributor.authorCher, Lawrence M-
dc.contributor.authorHovey, Elizabeth-
dc.contributor.authorWheeler, Helen-
dc.contributor.authorNowak, Anna K-
dc.date2017-05-22-
dc.date.accessioned2017-05-26T06:06:23Z-
dc.date.available2017-05-26T06:06:23Z-
dc.date.issued2017-07-
dc.identifier.citationJournal of Neuro-Oncology 2017; 133(3): 623-631en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16662-
dc.description.abstractIn recurrent glioblastoma, health-related quality of life (HRQL) is a crucial trial endpoint. We examined HRQL outcomes as a secondary endpoint for patients in the CABARET randomized phase 2 trial. 122 patients were randomly allocated to bevacizumab monotherapy or bevacizumab plus carboplatin. We calculated change scores from baseline for each HRQL measure on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and the Brain Cancer Module (QLQ-BN20), together with time to deterioration in HRQL, and the proportion of participants with clinically meaningful improvements in specific disease-related symptoms. At baseline, 117 of 122 randomized patients (96%) attempted questionnaires. Questionnaire participation rates were >90% for patients continuing on treatment, however at the end-of-treatment visit only 72 (64% of eligible participants) returned a form. There were no differences between arms in change scores over the treatment period. Time to ≥10 point deterioration in scores from baseline was also similar between arms. HRQL deterioration occurred largely before progression for the domains tested, but scores in HRQL domains specifically relevant to symptoms of recurrent glioblastoma also improved for about 50% of patients with symptoms at baseline. Neither detrimental nor beneficial effects on HRQL were seen with carboplatin added to bevacizumab, with a proportion of patients on both arms experiencing symptomatic benefit. Given the reduced questionnaire completion at end of treatment, time to HRQL deterioration is a feasible and robust clinical trial endpoint in this patient population. Clinical trials registration number: ACTRN12610000915055.en_US
dc.subjectBN20en_US
dc.subjectBevacizumaben_US
dc.subjectCarboplatinen_US
dc.subjectClinical trialen_US
dc.subjectGlioblastomaen_US
dc.subjectQLQ-C30en_US
dc.subjectQuality of lifeen_US
dc.titleHealth-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastomaen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJournal of Neuro-Oncologyen_US
dc.identifier.affiliationRoyal Melbourne Hospital, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationPsycho-oncology Co-operative Research Group (PoCoG), School of Psychology and Central Clinical School, Sydney Medical School, University of Sydney, Sydney, NSW, Australiaen_US
dc.identifier.affiliationNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australiaen_US
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationPrince of Wales Hospital, Barker Street, Randwick, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Medicine, University of New South Wales, Sydney, NSW, Australiaen_US
dc.identifier.affiliationRoyal North Shore Hospital, Pacific Highway, St Leonards, NSW, Australiaen_US
dc.identifier.affiliationSir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA, Australiaen_US
dc.identifier.affiliationSchool of Medicine and Pharmacology, University of Western Australia, 35 Stirling Highway, Crawley, WA, Australiaen_US
dc.type.studyortrialRandomized Controlled Clinical Trial/Controlled Clinical Trialen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/28534153en_US
dc.identifier.doi10.1007/s11060-017-2479-8en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherCher, Lawrence M
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.